SC
ADMA icon

Stephens Consulting’s ADMA Biologics ADMA Stock Holding History

Stephens Consulting’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60
Closed -$1.19K – 1200
2025
Q1 		$1.19K Buy
+60
New +$1.04K ﹤0.01% 570
2023
Q4 		– Sell
-10,000
Closed -$35.8K – 486
2023
Q3 		$35.8K Buy
+10,000
New +$38.5K 0.01% 200

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Stephens Consulting's ADMA Position: Q2 2025 in Review

Stephens Consulting sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 60 shares — an estimated $1.19K sold.

Stephens Consulting first reported a position in ADMA in Q3 2023 and held it in 2 quarters. The position peaked at $35.8K in Q3 2023. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

  • Stephens Consulting reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 60 ADMA Biologics shares in Q2 2025, an estimated $1.19K.
  • Stephens Consulting first reported a position in ADMA Biologics in Q3 2023 and held it in 2 quarters.
  • Stephens Consulting's ADMA Biologics position peaked at $35.8K in Q3 2023.
  • 368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.